The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Abstract
Purpose: To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS). Patients, Materials, and Methods: Overall, 193 patients with MDS and 65 healthy volunteers were examined for ASXL1 mutations by direct sequencing and for expression levels of ASXL1. The prognostic impact of ASXL1 mutation and expression levels was evaluated in the context of other clinical and molecular prognostic markers. Results: Mutations in ASXL1 occurred with a frequency of 20.7% in MDS (n = 40 of 193) with 70% (n = 28) of mutations being frameshift mutations and 30% (n = 12) being heterozygous point mutations leading to translational changes. ASXL1 mutations were correlated with an intermediate-risk karyotype (P = .002) but not with other clinical parameters. The presence of ASXL1 mutations was associated with a shorter overall survival for frameshift and point mutations combined (hazard ratio [HR], 1.744; 95% CI, 1.08 to 2.82; P = .024) and for frameshift mutations only (HR, 2.06; 95% CI, 1.21 to 3.50; P = .008). ASXL1 frameshift mutations were associated with a reduced time to progression of acute myeloid leukemia (AML; HR 2.35; 95% CI, 1.17 to 4.74; P = .017). In multivariate analysis, when considering karyotype, transfusion dependence, and IDH1 mutation status, ASXL1 frameshift mutations remained an independent prognostic marker in MDS (overall survival: HR, 1.85; 95% CI, 1.03 to 3.34; P = .040; time to AML progression: HR, 2.39; 95% CI, 1.12 to 5.09; P = .024). Conclusion: These results suggest that ASXL1 mutations are frequent molecular aberrations in MDS that predict an adverse prognostic outcome. Screening of patients for ASXL1 mutations might be useful for clinical risk stratification and treatment decisions in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E. R. L. T. M., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 755
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J., Larrayoz, M. J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., et al. (2010) · Leukemia · doi:10.1038/leu.2010.20 · Cited by 264
Heuser, M., Beutel, G., Krauter, J., Döhner, K., von Neuhoff, N., Schlegelberger, B., & Ganser, A. (2006) · Blood · doi:10.1182/blood-2006-04-014845 · Cited by 232
Self-citationChou, W.-C., Huang, H.-H., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283291 · Cited by 227
Gelsi‐Boyer, V., Trouplin, V., Roquain, J., Adélaïde, J., Carbuccia, N., Esterni, B., Finetti, P., Murati, A., Arnoulet, C., Zerazhi, H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08381.x · Cited by 222
Rezvani, K., Grube, M., Brenchley, J. M., Sconocchia, G., Fujiwara, H., Price, D. A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0150 · Cited by 211
Chou, W.-C., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 204
Thol, F., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 191
Self-citationPassweg, J. R., Giagounidis, A. A. N., Simcock, M., Aul, C., Dobbelstein, C., Stadler, M., Ossenkoppele, G., Hofmann, W.-K., Schilling, K., Tichelli, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2686 · Cited by 190
Self-citationFisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., Hess, J. L., Humphries, R. K., & Brock, H. W. (2009) · Blood · doi:10.1182/blood-2009-07-230698 · Cited by 174
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Censoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Cho, Y.-S., Kim, E., Park, U., Sin, H., & Um, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512616200 · Cited by 165
Stadler, M., Germing, U., Kliche, K. O., Josten, K., Kuse, R., Hofmann, W.-K., Schrezenmeier, H., Novotný, J., Anders, O., Eimermacher, H., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403239 · Cited by 138
Self-citationDamm, F., Heuser, M., Morgan, M. A., Yun, H., Großhennig, A., Göhring, G., Schlegelberger, B., Döhner, K., Ottmann, O. G., Lübbert, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0342 · Cited by 128
Self-citationMutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Carbuccia, N., Trouplin, V., Gelsi‐Boyer, V., Murati, A., Rocquain, J., Adélaı̈de, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.218 · Cited by 121
Fisher, C. L., Randazzo, F. M., Humphries, R. K., & Brock, H. W. (2006) · Gene · doi:10.1016/j.gene.2005.10.033 · Cited by 104
Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T. J., Kušec, R., Pellagatti, A., Wang, L., Clark, R. E., & Wainscoat, J. S. (2010) · Leukemia · doi:10.1038/leu.2010.65 · Cited by 91
Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
Heuser, M., Wingen, L. U., Steinemann, D., Cario, G., Neuhoff, N. V., Tauscher, M., Bullinger, L., Krauter, J., Heil, G., Döhner, H., et al. (2005) · PubMed · Cited by 84
Self-citationPerez, B., Kosmider, O., Cassinat, B., Renneville, A., Lachenaud, J., Kaltenbach, S., Bertrand, Y., Baruchel, A., Chomienne, C., Fontenay, M., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08393.x · Cited by 81
Sloand, E. M., Melenhorst, J. J., Tucker, Z. C. G., Pfannes, L. V., Brenchley, J. M., Yong, A. S. M., Visconte, V., Wu, C. O., Emma Gostick, D., Scheinberg, P., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277921 · Cited by 81
Abdel-Wahab, O. I., Kilpivaara, O., Patel, J. L., Busque, L., & Levine, R. L. (2010) · Leukemia · doi:10.1038/leu.2010.144 · Cited by 81
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations
Sugimoto, Y., Muramatsu, H., Makishima, H., Prince, C. J., Jankowska, A. M., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08196.x · Cited by 77
Myelodysplastic syndromes: biology and treatment
Jädersten, M., & Hellström‐Lindberg, E. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02052.x · Cited by 73
Mutation in TET2 in Myeloid Cancers
(2009) · New England Journal of Medicine · doi:10.1056/nejmc091348 · Cited by 66
Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes
Cazzola, M., & Malcovati, L. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.005 · Cited by 46
Oral iron chelators: Prospects for future development
Porter, J. B. (1989) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1989.tb00300.x · Cited by 36
A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders
Yoshida, K., Sanada, M., Kato, M., Kawahata, R., Matsubara, A., Takita, J., Shih, L.-Y., Mori, H., Koeffler, H. P., & Ogawa, S. Y. (2010) · Leukemia · doi:10.1038/leu.2010.241 · Cited by 20
Steensma, D. P. (2007) · Haematologica · doi:10.3324/haematol.11471 · Cited by 13
Cited by
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Thol, F., Kade, S., Schlarmann, C., Löffeld, P., Morgan, M., Krauter, J., Wlodarski, M. W., Kölking, B., Wichmann, M., Görlich, K., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399337 · Cited by 419
Self-citation
Metadata
- Authors
- Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O., Hofmann, W.-K., Schlegelberger, B., Heuser, M., & Ganser, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-20
- Volume
- 29
- Issue
- 18
- Pages
- 2499-2506
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2144878135
- Cited by
- 277
- References
- 37
- FWCI
- 18.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.